Vestal Point Capital’s Cytokinetics CYTK Stock Holding History

Vestal Point Capital’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-300,000	Closed	-$19.8M	–	77
2026 Q1	$19.8M	Buy	+300,000	New	+$19.1M	0.55%	49
2025 Q4	–	Sell	-725,000	Closed	-$39.8M	–	88
2025 Q3	$39.8M	Sell	725,000 -2,250,000	-76%	-$92.7M	1.8%	19
2025 Q2	$98.3M	Buy	2,975,000 +384,469	+15%	+$13.4M	5.18%	3
2025 Q1	$104M	Buy	2,590,531 +240,531	+10%	+$11.1M	7.44%	2
2024 Q4	$111M	Buy	2,350,000 +850,000	+57%	+$44.1M	6.55%	2
2024 Q3	$79.2M	Sell	1,500,000 -575,000	-28%	-$32M	6.01%	3
2024 Q2	$112M	Sell	2,075,000 -75,000	-3%	-$4.53M	8.38%	2
2024 Q1	$151M	Buy	2,150,000 +2,100,000	+4,200%	+$162M	12.47%	1
2023 Q4	$4.17M	Buy	+50,000	New	+$1.81M	0.44%	34

Other funds holding CYTK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vestal Point Capital's CYTK Position: Q2 2026 in Review

Vestal Point Capital sold out of Cytokinetics (CYTK) in Q2 2026, closing a stake of 300,000 shares — an estimated $19.8M sold.

Vestal Point Capital first reported a position in CYTK in Q4 2023 and held it in 9 quarters. The position peaked at $151M in Q1 2024. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

Vestal Point Capital reported no remaining Cytokinetics position as of Q2 2026 after selling out during the quarter.
Vestal Point Capital sold 300,000 Cytokinetics shares in Q2 2026, an estimated $19.8M.
Vestal Point Capital first reported a position in Cytokinetics in Q4 2023 and held it in 9 quarters.
Vestal Point Capital's Cytokinetics position peaked at $151M in Q1 2024.
482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Vestal Point Capital's 13F filing for Q2 2026, filed 14 Aug 2026.